Manufacturing Costs For Small Molecule Development Work

In Q3 2020, ISR asked 49 respondents to allocate the costs of development work and clinical trial materials for outsourced small molecule drugs. The data show that API Manufacturing and Drug Product Manufacturing and Process Development capture similar proportions of outsourced spend at this stage. To learn more about Small Molecule Costs by Activity, including how costs are allocated for commercial manufacturing, follow the link to the CDMO Outsourcing Models